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Noninvasive detection of solid-
organ transplant rejection
Snyder et al., Proc Natl Acad Sci USA 2011; 108: 6229–6234; doi:10.1073/
pnas.1013924108
For most transplanted organs, diagnosis of early rejection requires 
a biopsy and tissue analysis. However, biopsy of an internal organ is 
invasive, expensive, causes patient discomfort, and might result in 
serious complications. Furthermore, analysis of the obtained tissue 
is limited by sampling error and subjectivity in the analysis of the 
tissue. Thus, there has been considerable effort to develop noninva-
sive techniques that might replace or reduce the need for biopsies 
of transplanted organs. Much of this effort has focused on monitor-
ing the recipient’s immune response to detect the onset of rejection. 
For example, the expression profile of certain genes in peripheral 
blood mononuclear cells assayed from cardiac transplant recipi-
ents has been demonstrated to differ between quiescent patients 
and those with severe rejection episodes. The AlloMap molecu-
lar expression test is the first FDA-approved test based on this 
research and, when used in conjunction with clinical observation 
and echocardiograms, has been shown to safely reduce the number 
of biopsies performed without increasing the risk of serious cardio-
vascular events. Another noninvasive approach would be, instead 
of monitoring the recipient’s immune response, to directly assay 
the health of the donated organ. Snyder et al. recently reported the 
development of such an assay by measurement of the signature of 
dying cells from the organ in the cell-free DNA circulating in the 
recipient’s plasma. They used high-throughput shotgun sequenc-
ing (Figure) to develop a universal noninvasive approach to moni-
toring organ health. They analyzed cell-free DNA circulating in 
the blood of heart transplant recipients and observed significantly 
increased levels of cell-free DNA from the donor genome at times 
when an endomyocardial biopsy independently established the 
presence of acute cellular rejection. Their results demonstrate that 
cell-free DNA can be used to detect an organ-specific signature 
that correlates with rejection. This noninvasive test holds promise 
for replacing biopsies in solid-organ transplant recipients.
Juan Oliver
Intravenous erythropoietin in 
patients with ST-segment elevation 
myocardial infarction
Najjar et al., JAMA 2011; 305: 1863–1872; doi:10.1001/jama.2011.592
Trials in anemia management in chronic kidney disease have yielded 
surprising results, demonstrating an increased risk of cardiovascular 
events associated with the treatment of anemia or treatment target-
ing higher hemoglobin.1–3 Thrombocytosis has been theorized as 
the mechanism. Concurrently, research in animals suggests that fol-
lowing myocardial infarction (MI), animals receiving epoetin alfa 
had lesser degrees of apoptosis in the infarct area and less reperfusion 
injury. The REVEAL trial tested the effect of epoetin alfa in patients 
presenting with an ST-segment elevation MI (STEMI). Patients 
with STEMIs undergoing emergent percutaneous revasculariza-
tion underwent randomization to either epoetin alfa or placebo 
and received the study drug within 4 hours of reperfusion. The first 
phase of the study randomized a total of 92 patients in a 2:1 ratio to 
increasing doses of epoetin alfa (15,000, 30,000, or 60,000 units) or 
placebo. In the second phase, 131 patients were randomized in a 1:1 
ratio to 60,000 units of epoetin alfa or placebo. Cardiac magnetic 
resonance (CMR) imaging was performed within 2–6 days of drug 
administration and at 12 weeks. The size of infarctions did not dif-
fer between treatment arms either on the first CMR scan or on the 
second CMR scan. However, among patients older than 70 years, the 
infarct size was larger during the first week in the epoetin alfa group 
as compared with the group receiving placebo. Additionally, the risk 
of the composite outcome of death, MI, stroke, or stent thrombosis 
was greater in the group randomized to epoetin alfa, with events 
occurring in five patients as compared with zero in the group who 
received placebo. It is reasonable to conclude that epoetin alfa does 
not have the same benefit to people experiencing an MI as it does in 
the preclinical studies. The issue of greater infarct size in the elderly 
is an important consideration for patients with end-stage renal dis-
ease (ESRD). Although the greater risk detected here has not been 
confirmed in other studies, its potential as a safety signal must be 
considered carefully. Whether the risk seen with the single large dose 
of epoetin alfa in this population with normal kidney function may 
also be seen in patients with ESRD who are treated chronically with 
epoetin alfa and become acutely ill should be the subject of further 
consideration, discussion, and research in nephrology.
Lynda Szczech
1N Engl J Med 1998; 339: 584–590. 2N Engl J Med 2006; 355: 2085–2098. 3N Engl J Med 
2009; 361: 2019–2032.
Healthy Acute cellular rejection
1. Collect cell-free
DNA from
plasma 
2. Perform shotgun
sequencing; identify
reads with donor and
recipient SNP calls
to calculate 
% donor DNA
3. Monitor donor DNA
level over time
to detect onset of
rejection
General scheme for this study. Cell-free DNA collected in plasma contains 
a majority of molecules from the recipient (in gray) but may also include 
some from the transplanted organ (green). Due to increased cell 
death in the organ during a rejection episode, more donor molecules 
are expected to be present in the blood at these times. SNP, single-
nucleotide polymorphism.
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Critical importance of blood 
pressure level in diabetes
Chen et al., Hypertension 2011; 57: 891–897; doi:10.1161/
HYPERTENSIONAHA.110.162446
In rich societies, hypertension and diabetes mellitus (DM) 
are highly prevalent conditions that coexist in many patients. 
Hypertension is significantly more common in individuals with 
DM than in the general population, with estimates of the preva-
lence of hypertension in diabetics ranging from 40% to 80%. 
DM alone is associated with increased cardiovascular diseases 
and death, but it is unclear whether this risk is because of the 
DM per se or because of concomitant hypertension. Indeed, 
trials of glucose lowering in individuals with DM have reported 
disappointingly small benefits for myocardial infarction, stroke, 
or death. Accordingly, Chen et al. aimed to determine how 
much of the risk of cardiovascular disease in individuals with 
DM might be attributable to hypertension. They retrospectively 
analyzed prospectively collected data from the Framingham 
original and offspring cohorts. Of the 1145 Framingham sub-
jects newly diagnosed with DM who did not have a previous 
history of cardiovascular events, 663 (58%) had hypertension 
at the time that DM was diagnosed. During 4154 person-years 
of follow-up, 125 died, and 204 experienced a cardiovascular 
event. Framingham participants with hypertension at the time 
of DM diagnosis exhibited significantly higher rates of all-cause 
mortality and cardiovascular events compared with normo-
tensive subjects with DM. After adjustment for demographic 
and clinical covariates, hypertension was associated with a 72% 
increase in the risk of all-cause death and a 57% increase in the 
risk of any cardiovascular event in individuals with DM. The 
population attributable risk from hypertension in individuals 
with DM was 30% for all-cause death and 25% for any car-
diovascular event. In contrast, after adjustment for concurrent 
hypertension, the population attributable risk from DM in 
Framingham subjects was 7% for all-cause mortality and 9% for 
any cardiovascular disease event. Thus, although DM was asso-
ciated with increased risks of death and cardiovascular events, 
most of this excess risk was attributable to coexistent hyperten-
sion. This study further supports the importance of good blood 
pressure control in patients with diabetes mellitus.
Juan Oliver
Tamm–Horsfall protein-deficient 
thick ascending limbs promote 
injury to neighboring S3 segments 
in an MIP-2-dependent mechanism
El-Achkar et al., Am J Physiol Renal Physiol 2011; 300: F999–F1007; 
doi:10.1152/ajprenal.00621.2010
Tamm–Horsfall protein (THP) is a glycoprotein exclusively 
expressed in the kidney, in thick ascending limbs (TALs), 
and early distal tubules. THP is a defense agent against stone 
formation and bladder infections, but its role in acute kidney 
injury (AKI), if any, is not well understood. El-Achkar et al. 
recently described a novel protective role of THP against AKI 
via downregulation of inflammation in the outer medulla. Their 
most recent study investigates the mechanistic relationships 
among the status of THP, inflammation, and tubular injury. 
Using an ischemia/reperfusion (I/R) model in wild-type and 
THP–/– mice, the authors demonstrate that the S3 proximal 
segments, but not the THP-deficient TAL, are the main targets 
of tubular injury during AKI. The injured S3 segments that 
are surrounded by neutrophils in THP–/– mice have marked 
overexpression of the neutrophil chemoattractant macrophage 
inflammatory protein-2 (MIP-2) as compared with those in 
their wild-type counterparts. Neutralizing MIP-2 antibody res-
cues S3 segments from injury, decreases neutrophil infiltration, 
and improves kidney function in THP–/– mice. Furthermore, 
using immunofluorescence volumetric imaging of wild-type 
mouse kidneys, the authors show that ischemia alters the intra-
cellular translocation of THP in the TAL cells by partially shift-
ing it from its default apical surface domain to the basolateral 
domain, which is contiguous to the basolateral surface of S3 
segments. Concomitant with this is the upregulation, in the 
basolateral surface of S3 segments, of the scavenger receptor 
SRB-1, a putative receptor for THP. The TAL affects the sus-
ceptibility of S3 segments to injury at least in part by regulating 
MIP-2 expression in a THP-dependent manner.
This paper confirms previous findings that neutralization of 
MIP-2 reduced neutrophil infiltration and susceptibility to kid-
ney injury. The finding of the ischemia-induced translocation of 
THP in the TAL cells and upregulation of SRB-1 is original and 
forms a solid foundation for further study of the role of THP 
in mediating TAL–S3 interactions during injury. Other inflam-
matory cells that play a role in the process of I/R of the kidney 
(T cells, macrophages, dendritic cells) should be studied in this 
model. These interesting findings raise the possibility of a direct 
role of basolaterally released THP in regulating inflammation in 
S3 segments (Figure).
Marc De Broe 
Possible mechanisms of THP-mediated tubular cross-talk between S3 
segments and TAL. Model A: Basolateral/interstitial THP released from the 
TAL acts directly on S3 segments. Model B: Alternatively, THP affects the 
TAL, which in turn releases a secondary mediator that acts on S3 tubules. 
Another possible ‘hybrid’ mechanism (not depicted here) could involve 
THP in the interstitium affecting S3 not directly but rather through an 
effect on interstitial or endothelial cells.
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